Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMELPHALAN HYDROCHLORIDE (melphalan hydrochloride) by Viatris (2) is clinical pharmacology melphalan is an alkylating agent of the bischloroethylamine type. Approved for myeloma. First approved in 2009.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Melphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N position of guanine. Like other bifunctional alkylating agents, it is…
Worked on MELPHALAN HYDROCHLORIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo